- Home
- BLNK vs MCRB Comparison
BLNK vs MCRB Comparison
Compare BLNK & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- MCRB
- Stock Information
- Founded
- BLNK 2009
- MCRB 2010
- Country
- BLNK United States
- MCRB United States
- Employees
- BLNK N/A
- MCRB N/A
- Industry
- BLNK Industrial Specialties
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- MCRB Health Care
- Exchange
- BLNK Nasdaq
- MCRB Nasdaq
- Market Cap
- BLNK 77.3M
- MCRB 65.5M
- IPO Year
- BLNK N/A
- MCRB 2015
- Fundamental
- Price
- BLNK $0.92
- MCRB $10.83
- Analyst Decision
- BLNK Buy
- MCRB Hold
- Analyst Count
- BLNK 8
- MCRB 4
- Target Price
- BLNK $2.61
- MCRB $73.67
- AVG Volume (30 Days)
- BLNK 4.3M
- MCRB 97.4K
- Earning Date
- BLNK 08-06-2025
- MCRB 08-12-2025
- Dividend Yield
- BLNK N/A
- MCRB N/A
- EPS Growth
- BLNK N/A
- MCRB N/A
- EPS
- BLNK N/A
- MCRB 8.98
- Revenue
- BLNK $109,383,000.00
- MCRB N/A
- Revenue This Year
- BLNK N/A
- MCRB N/A
- Revenue Next Year
- BLNK $31.15
- MCRB N/A
- P/E Ratio
- BLNK N/A
- MCRB $1.24
- Revenue Growth
- BLNK N/A
- MCRB N/A
- 52 Week Low
- BLNK $0.63
- MCRB $6.53
- 52 Week High
- BLNK $3.75
- MCRB $30.60
- Technical
- Relative Strength Index (RSI)
- BLNK 62.97
- MCRB 64.96
- Support Level
- BLNK $0.85
- MCRB $7.17
- Resistance Level
- BLNK $0.98
- MCRB $9.78
- Average True Range (ATR)
- BLNK 0.09
- MCRB 0.66
- MACD
- BLNK 0.01
- MCRB 0.27
- Stochastic Oscillator
- BLNK 71.43
- MCRB 89.66
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.